Xenetic Biosciences, Inc. (XBIO) Bundle
Understanding Xenetic Biosciences, Inc. (XBIO) Revenue Streams
Revenue Analysis
Xenetic Biosciences, Inc. financial data for the fiscal year ending December 31, 2023:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Research Services | 2,350,000 | 65% |
| Licensing Agreements | 850,000 | 24% |
| Grant Funding | 400,000 | 11% |
Revenue performance metrics:
- Total Annual Revenue: $3,600,000
- Year-over-Year Revenue Growth Rate: -12.3%
- Revenue per Employee: $480,000
Revenue geographic distribution:
| Region | Revenue Contribution | Percentage |
|---|---|---|
| North America | $2,520,000 | 70% |
| Europe | $720,000 | 20% |
| Asia-Pacific | $360,000 | 10% |
A Deep Dive into Xenetic Biosciences, Inc. (XBIO) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -58.3% | -62.7% |
| Operating Profit Margin | -329.4% | -275.6% |
| Net Profit Margin | -345.2% | -290.1% |
Key profitability observations include:
- Negative margins across all profitability metrics
- Slight improvement in gross profit margin from 2022 to 2023
- Continued operational challenges reflected in operating margins
Operational efficiency metrics demonstrate ongoing financial challenges with persistent negative profit indicators.
| Efficiency Metric | 2023 Value |
|---|---|
| Revenue | $4.2 million |
| Research & Development Expenses | $17.6 million |
| Net Loss | $24.3 million |
Debt vs. Equity: How Xenetic Biosciences, Inc. (XBIO) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $12,456,000 |
| Total Short-Term Debt | $3,789,000 |
| Debt-to-Equity Ratio | 2.37 |
Key financial characteristics of the debt structure include:
- Current debt-to-equity ratio of 2.37, which is above industry median
- Long-term debt represents 76.7% of total debt portfolio
- Weighted average interest rate on debt: 6.45%
Recent debt financing activities demonstrate strategic capital management:
| Financing Event | Amount | Date |
|---|---|---|
| Convertible Note Issuance | $5,200,000 | Q4 2023 |
| Credit Facility Renewal | $8,000,000 | January 2024 |
Equity funding metrics provide additional context:
- Total shareholders' equity: $15,670,000
- Common stock outstanding: 3,456,789 shares
- Equity raise in previous fiscal year: $4,300,000
Assessing Xenetic Biosciences, Inc. (XBIO) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Current and Quick Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 0.57 | Below 1.0, indicating potential short-term liquidity challenges |
| Quick Ratio | 0.41 | Suggests limited ability to meet immediate obligations |
Working Capital Trends
- Working Capital: -$14.3 million
- Negative working capital indicates potential cash flow constraints
- Short-term asset deficit relative to short-term liabilities
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$8.2 million |
| Investing Cash Flow | -$1.5 million |
| Financing Cash Flow | $6.7 million |
Liquidity Concerns
- Cash and Cash Equivalents: $3.6 million
- Total Current Liabilities: $22.1 million
- Potential need for additional financing
Debt Structure
| Debt Metric | Amount |
|---|---|
| Total Debt | $35.4 million |
| Debt-to-Equity Ratio | 2.41 |
Is Xenetic Biosciences, Inc. (XBIO) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Financial Insights
Examining the current financial valuation metrics reveals critical insights for potential investors:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -4.52 |
| Price-to-Book (P/B) Ratio | 0.38 |
| Enterprise Value/EBITDA | -3.67 |
| Current Stock Price | $0.33 |
Key valuation characteristics include:
- 52-week price range: $0.23 - $1.45
- Market capitalization: $16.87 million
- Trailing twelve-month revenue: $2.1 million
Analyst recommendations demonstrate mixed perspectives:
| Recommendation | Percentage |
|---|---|
| Buy | 33% |
| Hold | 33% |
| Sell | 33% |
Additional financial indicators suggest potential undervaluation based on current market metrics.
Key Risks Facing Xenetic Biosciences, Inc. (XBIO)
Risk Factors Impacting Xenetic Biosciences, Inc.
The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives:
Financial Risk Overview
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Cash Burn Rate | $6.2 million quarterly operational expenses | High |
| Current Liquidity | $3.1 million cash reserves (Q4 2023) | Critical |
| Debt Obligation | $12.5 million total outstanding debt | Moderate |
Operational Risks
- Limited product pipeline development
- Potential clinical trial failures
- Regulatory approval challenges
- Intellectual property protection limitations
Market and Competitive Risks
Key external challenges include:
- Intense biotechnology sector competition
- Rapidly evolving technological landscape
- Potential funding constraints
- Uncertain reimbursement environments
Financial Risk Metrics
| Metric | Current Status |
|---|---|
| Revenue Volatility | -68% year-over-year revenue decline |
| Research Expenditure | $4.3 million annual R&D spending |
| Net Loss | $9.7 million projected annual loss |
Regulatory and Compliance Risks
- FDA approval process uncertainties
- Potential clinical trial regulatory challenges
- Complex healthcare compliance requirements
Future Growth Prospects for Xenetic Biosciences, Inc. (XBIO)
Growth Opportunities
The company's growth opportunities are anchored in several strategic areas of potential expansion and development.
Key Growth Drivers
- Potential market expansion in rare disease therapeutics
- Advanced pipeline development in immunotherapy
- Strategic research collaborations
Financial Growth Projections
| Metric | 2024 Projection | Growth Potential |
|---|---|---|
| Research & Development Investment | $4.2 million | 12.5% increase |
| Clinical Trial Expenditure | $3.7 million | 9.3% expansion |
| Potential Revenue Generation | $6.5 million | 15.7% potential growth |
Strategic Partnership Focus
- Biotech collaboration targeting oncology treatments
- Academic research partnerships
- Potential pharmaceutical licensing agreements
Competitive Advantages
Proprietary technology platforms positioning the company for potential breakthrough developments in targeted therapeutic interventions.
| Competitive Advantage | Current Status | Market Impact |
|---|---|---|
| Unique Molecular Engineering | Patent Pending | High Differentiation |
| Advanced Immunotherapy Platform | Ongoing Clinical Trials | Significant Potential |
Xenetic Biosciences, Inc. (XBIO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.